Business
Nutriband Supports Newly Published CDC Opioid Prescribing Guidelines
New guidelines reiterate need for abuse deterrent technologies and call for enabling clinicians to provide comprehensive pain management including appropriate
About this update from Nutriband Inc.
[{"type":"text","content":"New guidelines reiterate need for abuse deterrent technologies and call for enabling clinicians to provide comprehensive pain management including appropriate use of opioid medicationsORLANDO, FL / ACCESSWIRE / November 8, 2022 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) supports the new United States Centers for Disease Control and Prevention (CDC) clinical practice guideline entitled \"CDC Clinical Practice Guideline for Prescribing Opioids for Pain - United States, 2022\" published on November 4, 2022.1 These guidelines are an update to the 2016 clinical practice guideline and allows prescribers to implement comprehensive and holistic pain management including responsible opioid use particularly for patients with moderate to severe chronic pain.The draft updated guidelines were posted for public comment earlier this year and the feedback was overwhelmingly in favor of easing the restrictions on opioid prescribers to allow patients who can benefit from opioids to get the access they need while still employing risk mitigation strategies to reduce the abuse and misuse of opioids. There is consensus from the pain management community that the misapplication of the 2016 guidelines resulted in an environment that has adversely affected patients, prescribers and caregivers who have few options to manage severe or intractable pain and has had minimal impact on opioid abusers as indicated by the continued rise in opioid overdose deaths.An important change in the new guideline is the removal of the perceived artificial dose threshold in the 2016 guidelines of 90 morphine milligram equivalent (MME) which has often been mistaken for a mandate along with warnings against abrupt opioid dose reduction or tapering.. Such misapplication, including inflexible application of recommended dosage and duration thresholds, contributed to patient harms, including untreated and undertreated pain, rapid opioid tapers and abrupt discontinuations, acute withdrawal symptoms, and psychological distress, in some cases leading to suicidal ideation and behavior.2 This translated into reduced prescribing of opioids for patients who have intractable severe chronic pain and for whom there are limited other options available. The CDC continues to recommend that clinicians should carefully evaluate a decision to increase opioid dosage based on an individualized a...